US2011129477A1PendingUtilityA1

NOGO Receptor Homologs

53
Assignee: STRITTMATTER STEPHEN MPriority: Oct 6, 2000Filed: Nov 23, 2010Published: Jun 2, 2011
Est. expiryOct 6, 2020(expired)· nominal 20-yr term from priority
A61P 43/00A61P 25/00G01N 2500/00C07K 14/705G01N 33/74G01N 33/6896C07K 16/28
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.

Claims

exact text as granted — not AI-modified
1 - 3 . (canceled) 
     
     
         4 . An isolated nucleic acid encoding the polypeptide of SEQ ID NO: 2. 
     
     
         5 - 16 . (canceled) 
     
     
         17 . An isolated polypeptide comprising an amino sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:14. 
     
     
         18 - 22 . (canceled) 
     
     
         23 . An isolated antibody that binds to the polypeptide of  claim 17 . 
     
     
         24 - 25 . (canceled) 
     
     
         26 . A method of decreasing inhibition of axonal growth of a CNS neuron, comprising the step of contacting the neuron with an effective amount of the polypeptide of  claim 17 . 
     
     
         27 . A method of treating a central nervous system disease, disorder or injury, comprising administering to a mammal an effective amount of the polypeptide of  claim 17 . 
     
     
         28 . A method of decreasing inhibition of axonal growth of a CNS neuron comprising the step of contacting the neuron with an effective amount of the antibody according to  claim 23 . 
     
     
         29 . A method of treating a central nervous system disease, disorder or injury, comprising administering to a mammal an effective amount of the antibody according to  claim 23 . 
     
     
         30 . A method for identifying a molecule that binds the polypeptide of  claim 17  comprising:
 (a) providing the polypeptide of  claim 17 ; 
 (b) contacting the polypeptide with a candidate molecule; 
 (c) detecting binding of the candidate molecule to said polypeptide.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.